<DOC>
	<DOC>NCT02004093</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of pertuzumab in combination with carboplatin-based standard chemotherapy in patients with platinum-sensitive recurrent ovarian cancer. The anticipated time on study treatment is 3-12 months.</brief_summary>
	<brief_title>A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pertuzumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>histologically confirmed ovarian, primary peritoneal, or fallopian tube cancer; only 1 previous regimen, which must be platinumbased; platinumsensitive disease which is defined by a progressionfree interval of greater than 6 months after completion of platinumbased chemotherapy. previous radiotherapy; previous treatment with an anticancer vaccine or any targeted therapy; major surgery or traumatic injury within 4 weeks of study; history or evidence of central nervous system metastases.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>